2022 Publications

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

Thummuri, D.; Khan, S.; Underwood, P. W.; Zhang, P.; Wiegand, J.; Zhang, X.; Budamagunta, V.; Sobh, A.; Tagmount, A.; Loguinov, A.; Riner, A. N.; Akki, A. S.; Williamson, E.; Hromas, R.; Vulpe, C. D.; Zheng, G.*; Trevino, J. G.*; Zhou, D.* Molecular Cancer Therapeutics. 2021, 21(1), 184-192. Doi: 10.1158/1535-7163.MCT-21-0474